BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BG Medicine IPO Expects $71M in IPO


12/13/2010 8:03:29 AM

Boston Business Journal - by Kyle Alspach -- BG Medicine Inc. is expected to announce an initial public offering of up to $71.2 million next week, according to IPO tracker Renaissance Capital.

The Waltham, Mass.-based developer of biomarker-based diagnostic tools is expected to price the roughly 4.7 million shares in the range of $13 to $15, according to Renaissance Capital. BG Medicine is seeking to sell its shares on the Nasdaq Stock Market under the symbol “BGMD.”

The company expects to use up to $25 million of the net proceeds from the offering to fund the commercial launch of its lead product, BGM Galectin-3, according to a filing with the U.S. Securities and Exchange Commission. The company received approval from the U.S. Food and Drug Administration for the cardiac test in November.

BG Medicine also plans to use up to $15 million from the offering to fund development, potential regulatory submission and potential commercial launch activities for other cardiovascular diagnostic products, according to the SEC filing.

BG, founded in 2000, first filed for an $80 million IPO on Euronext in August 2007, before abandoning it just a few months later, in January 2008. The company re-filed for an IPO with the SEC in January.

BG Medicine reported revenue of $620,000 and a net loss of $13.8 million for the first nine months of the year, according to the SEC filing.

Flagship Ventures is the largest pre-IPO shareholder. The Cambridge, Mass.-based venture firm holds 44.4 percent of the company’s value, and Flagship partner Noubar Afeyan is the chairman of BG’s board.

The next-largest shareholder is the Gilde Europe Food and Agriculture Fund BV, with 14.6 percent. Other investors include GE Asset Management, Humana Inc., Koninklijke Philips Electronics N.V., Legg Mason Capital management and SMALLCAP World Fund.



   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES